Tyvaso approved for pulmonary arterial hypertension (PAH) - MPR
Links shared publicly online about this topic.
- 1,859total visits
Tyvaso approved for pulmonary arterial hypertension (PAH) - MPR
empr.com —
View full resource at empr.com
Tags: Heart Disease, High Blood Pressure, FDA, Pulmonology, News
Most Recently Shared on July 30, 2009 at 8:18 pm By:
MPR News: Tyvaso approved for pulmonary arterial hypertension (PAH): The FDA has approved Tyvaso (trepr.. http://bit.ly/UGQxc
Children With PAH May Benefit From Sildenafil
medicalnewstoday.com — “Sildenafil is currently approved for adult pulmonary arterial hypertension (PAH); however, new research presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians” View full resource at medicalnewstoday.com
Most Recently Shared on October 25, 2011 at 10:05 am By:
MNT Pediatrics News Pediatrics and Health News
Children With PAH May Benefit From Sildenafil http://t.co/YLI8BfnH #pediatrics
Pfizer's Revatio extends Europe PAH licence | InPharm
inpharm.com — “Pfizer--™s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children” View full resource at inpharm.com
Most Recently Shared on May 9, 2011 at 11:54 am By:
Pharmafocus Health News and Pharma
Pfizer's Revatio extends Europe PAH licence http://goo.gl/fb/EsYqT
FDA approves change to prescribing information for Gilead Sciences' Letairis
news-medical.net — “Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.” View full resource at news-medical.net
Most Recently Shared on March 5, 2011 at 12:03 pm By:
Pregnancy News: FDA approves change to prescribing information for Gilead Sciences' Letairis: Gilead Sciences, I... http://bit.ly/hi39GH
Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies
news-medical.net — “Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.” View full resource at news-medical.net
Most Recently Shared on December 10, 2010 at 2:26 pm By:
Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies: Pfizer Inc. announced today ... http://bit.ly/gpe43Q
United Therapeutics Corporation - FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
ir.unither.com — “United Therapeutics Corporation - FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension” View full resource at ir.unither.com
Most Recently Shared on July 31, 2009 at 1:12 pm By:
Dr. Warren Rosenblum Doctor, Internist, Cardiologist, and Physician
FDA approves inhaled Treprostinil (Tyvaso) for the treatment of Pulmonary Hypertension. http://tinyurl.com/kw89ks
FDA Approves Tyvaso (treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
drugs.com — “Tyvaso (treprostinil) is used to treat Pulmonary Arterial Hypertension. Includes Tyvaso side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 31, 2009 at 3:51 am By:
FDA Approves Tyvaso (treprostinil) Inhalation Solution for Pulmonary Arterial Hypertension - http://bit.ly/w1huZ
FDA Approves Tadalafil for Pulmonary Hypertension
fdanews.com — “United Therapeutics has received FDA clearance to market Adcirca, its pulmonary arterial hypertension (PAH) drug.” View full resource at fdanews.com
Most Recently Shared on June 16, 2009 at 6:29 pm By:
Dr. Warren Rosenblum Doctor, Internist, Cardiologist, and Physician
Tadalafil approved by FDA for treatment of PAH http://tinyurl.com/nqjonv
Tadalafil for PAH
theheart.org — “Tadalafil is a phosphodiesterase type-5 inhibitor and is now available in the 40-mg dose for the purpose of increasing exercise capacity in patients with WHO class 1 PAH.” View full resource at theheart.org
Most Recently Shared on May 28, 2009 at 9:01 pm By:
heartwire: PHIRST published, and tadalafil approved for pulmonary arterial hypertension http://bit.ly/N0KCz
Advertisement
